Non-Small-Cell Lung Cancer | Disease Landscape and Forecast | G7 | 2017
NSCLC has one of the most dynamic drug development pipelines in oncology, including multiple targeted and biomarker-driven therapies. DRG expects the NSCLC therapy market to experience robust growth throughout the 2016-2026 forecast period. The biggest driver of market sales growth will be the continued uptake and anticipated label expansions of immune checkpoint inhibitors. Merck & ;s Keytruda became the first immune checkpoint inhibitor to receive approval for first-line NSCLC and is anticipated to generate significant sales in this setting. EGFR and ALK inhibitor drug classes will also contribute to market growth following the first-line label expansions of Tagrisso and Alecensa, respectively. Several new therapies will gain approvals within the forecast period, from four different drug classes, resulting in increased therapy options and a highly competitive market. Questions Answered
How large are the drug-treatable NSCLC populations and how will the drug-treatment rates change over time?
What is the current state of treatment in NSCLC ? What are interviewed experts’ insights on current treatment options? What clinical needs remain unfulfilled?
How will different immune checkpoint inhibitor regimens compete in the first-line metastatic NSCLC setting? What will patient share dynamics look like in high PD-L1 ( TPS ≥50%) and negative/low- PD-L1 patient segments?
What will be the therapy options for EGFR – and ALK -positive patients following progression on first-line Tagrisso and Alecensa, respectively?
What pipeline products are most promising, and what sales/uptake could they secure in NSCLC ? What therapies of note are progressing in earlier phases?
What are the drivers and constraints in the NSCLC market, and how will the market evolve over the forecast period?
Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.